CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$55.79
−1.24%Aug 13, 2026, 07:38 UTC
Bank of America Corp DE reduced its stake in CRISPR Therapeutics AG by 10.4% during the first quarter, selling 113,815 shares and retaining 983,072 shares, as disclosed in a recent SEC filing.
Source:Aug 5, 2026, 14:09 UTC
CRISPR Therapeutics announced that CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.
Source:Aug 5, 2026, 14:09 UTC
CRISPR Therapeutics reported that CASGEVY achieved $76 million in Q2 2026 sales, up 151% year-over-year, and is now targeting sickle cell disease and transfusion-dependent beta thalassemia patients as young as 2 years old.
Source:Aug 3, 2026, 20:15 UTC
CRISPR Therapeutics reported its financial results for the second quarter ended June 30, 2026, on August 3, 2026.
Jun 4, 2026, 00:00 UTC
CRISPR Therapeutics AG elected Samarth Kulkarni as Chairman of the Board of Directors and Ali Behbahani, Maria Fardis, H. Edward Fleming Jr., and Simeon J. George as members of the Board of Directors, effective June 4, 2026.